The largest generic drugmaker in the world, Teva Pharmaceutical Industries, has reportedly posted a wonderful fourth quarter result with a rise in the net profit. The net profit is basically due to the acquisition of Barr and also the high sales of Copaxone, their treatment for multiple sclerosis.